This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Alaiya A., Roblick U., Egevad L., Carlsson A., Franzén B., Volz D., Huwendiek S., Linder S., Auer G.: Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal. Cell. Pathol., 2000; 21: 1–9AlaiyaA.RoblickU.EgevadL.CarlssonA.FranzénB.VolzD.HuwendiekS.LinderS.AuerG.Polypeptide expression in prostate hyperplasia and prostate adenocarcinomaAnal. Cell. Pathol.2000211910.1155/2000/351963461842011254220Search in Google Scholar
Alfonso P., Núñez A., Madoz-Gurpide J., Lombardia L., Sánchez L., Casal J.I.: Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics, 2005; 5: 2602–2611AlfonsoP.NúñezA.Madoz-GurpideJ.LombardiaL.SánchezL.CasalJ.I.Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresisProteomics200552602261110.1002/pmic.20040119615924290Search in Google Scholar
Araki M., Yang Y., Masubuchi N., Hironaka Y., Takei H., Morishita S., Mizukami Y., Kan S., Shirane S., Edahiro Y., Sunami Y., Ohsaka A., Komatsu N.: Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood, 2016; 127: 1307–1316ArakiM.YangY.MasubuchiN.HironakaY.TakeiH.MorishitaS.MizukamiY.KanS.ShiraneS.EdahiroY.SunamiY.OhsakaA.KomatsuN.Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasmsBlood20161271307131610.1182/blood-2015-09-67117226817954Search in Google Scholar
Arshad N., Cresswell P.: Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J. Biol. Chem., 2018; 293: 9555–9569ArshadN.CresswellP.Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-IJ. Biol. Chem.20182939555956910.1074/jbc.RA118.002836601647329769311Search in Google Scholar
Chachoua I., Pecquet C., El-Khoury M., Nivarthi H., Albu R.I., Marty C., Gryshkova V., Defour J.P., Vertenoeil G., Ngo A., Koay A., Raslova H., Courtoy P.J., Choong M.L., Plo I., et al.: Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood, 2016; 127: 1325–1335ChachouaI.PecquetC.El-KhouryM.NivarthiH.AlbuR.I.MartyC.GryshkovaV.DefourJ.P.VertenoeilG.NgoA.KoayA.RaslovaH.CourtoyP.J.ChoongM.L.PloI.Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutantsBlood20161271325133510.1182/blood-2015-11-68193226668133Search in Google Scholar
Chahed K., Kabbage M., Ehret-Sabatier L., Lemaitre-Guillier C., Remadi S., Hoebeke J., Chouchane L.: Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: The two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses. Int. J. Oncol., 2005; 27: 1425–1431ChahedK.KabbageM.Ehret-SabatierL.Lemaitre-GuillierC.RemadiS.HoebekeJ.ChouchaneL.Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: The two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analysesInt. J. Oncol.2005271425143110.3892/ijo.27.5.1425Search in Google Scholar
Chang H.H., Lee H., Hu M.K., Tsao P.N., Juan H.F., Huang M.C., Shih Y.Y., Wang B.J., Jeng Y.M., Chang C.L., Huang S.F., Tsay Y.G., Hsieh F.J., Lin K.H., Hsu W.M., et al.: Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma. Clin. Cancer Res., 2010; 16: 4411–4420ChangH.H.LeeH.HuM.K.TsaoP.N.JuanH.F.HuangM.C.ShihY.Y.WangB.J.JengY.M.ChangC.L.HuangS.F.TsayY.G.HsiehF.J.LinK.H.HsuW.M.Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastomaClin. Cancer Res.2010164411442010.1158/1078-0432.CCR-09-336020736329Search in Google Scholar
Chao M.P., Jaiswal S., Weissman-Tsukamoto R., Alizadeh A.A., Gentles A.J., Volkmer J., Weiskopf K., Willingham S.B., Raveh T., Park C.Y., Majeti R., Weissman I.L.: Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counter-balanced by CD47. Sci. Transl. Med., 2010; 2: 63ra94ChaoM.P.JaiswalS.Weissman-TsukamotoR.AlizadehA.A.GentlesA.J.VolkmerJ.WeiskopfK.WillinghamS.B.RavehT.ParkC.Y.MajetiR.WeissmanI.L.Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counter-balanced by CD47Sci. Transl. Med.2010263ra9410.1126/scitranslmed.3001375412690421178137Search in Google Scholar
Chiang W.F., Hwang T.Z., Hour T.C., Wang L.H., Chiu C.C., Chen H.R., Wu Y.J., Wang C.C., Wang L.F., Chien C.Y., Chen J.H., Hsu C.T., Chen J.Y.F.: Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma. Oral Oncol., 2013; 49: 534–541ChiangW.F.HwangT.Z.HourT.C.WangL.H.ChiuC.C.ChenH.R.WuY.J.WangC.C.WangL.F.ChienC.Y.ChenJ.H.HsuC.T.ChenJ.Y.F.Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinomaOral Oncol.20134953454110.1016/j.oraloncology.2013.01.00323375593Search in Google Scholar
Cid N.D., Jeffery E., Rizvi S.M., Stamper E., Peters L.R., Brown W.C., Provoda C., Raghavan M.: Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway. J. Biol. Chem., 2010; 285: 4520–4535CidN.D.JefferyE.RizviS.M.StamperE.PetersL.R.BrownW.C.ProvodaC.RaghavanM.Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathwayJ. Biol. Chem.20102854520453510.1074/jbc.M109.085407283605719959473Search in Google Scholar
Cockram T.O.J., Puigdellívol M., Brown G.C.: Calreticulin and galectin-3 opsonise bacteria for phagocytosis by microglia. Front. Immunol., 2019; 10: 2647CockramT.O.J.PuigdellívolM.BrownG.C.Calreticulin and galectin-3 opsonise bacteria for phagocytosis by microgliaFront. Immunol.201910264710.3389/fimmu.2019.02647686138131781126Search in Google Scholar
Coppolino M.G., Woodside M.J., Demaurex N., Grinstein S., St-Arnaud R., Dedhar S.: Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature, 1997; 386: 843–847CoppolinoM.G.WoodsideM.J.DemaurexN.GrinsteinS.St-ArnaudR.DedharS.Calreticulin is essential for integrin-mediated calcium signalling and cell adhesionNature199738684384710.1038/386843a09126744Search in Google Scholar
Cordua S., Kjaer L., Skov V., Pallisgaard N., Hasselbalch H.C., Ellervik C.: Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood, 2019; 134: 469–479CorduaS.KjaerL.SkovV.PallisgaardN.HasselbalchH.C.EllervikC.Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general populationBlood201913446947910.1182/blood.201900111331217187Search in Google Scholar
Di Martino S., Crescente G., De Lucia V., Di Paolo M., Marotta G., De Lucia D., Abbadessa A.: The emerging role of calreticulin in cancer cells. World Cancer Res. J., 2017; 4: e926Di MartinoS.CrescenteG.De LuciaV.Di PaoloM.MarottaG.De LuciaD.AbbadessaA.The emerging role of calreticulin in cancer cellsWorld Cancer Res. J.20174e926Search in Google Scholar
Du X.L., Hu H., Lin D.C., Xia S.H., Shen X.M., Zhang Y., Luo M.L., Feng Y.B., Cai Y., Xu X., Han Y.L., Zhan Q.M., Wang M.R.: Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J. Mol. Med., 2007; 85: 863–875DuX.L.HuH.LinD.C.XiaS.H.ShenX.M.ZhangY.LuoM.L.FengY.B.CaiY.XuX.HanY.L.ZhanQ.M.WangM.R.Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinomaJ. Mol. Med.20078586387510.1007/s00109-007-0159-417318615Search in Google Scholar
Eder-Azanza L., Navarro D., Aranaz P., Novo F.J., Cross N.C., Vizmanos J.L.: Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling. Leukemia, 2014; 28: 2106–2109Eder-AzanzaL.NavarroD.AranazP.NovoF.J.CrossN.C.VizmanosJ.L.Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signalingLeukemia2014282106210910.1038/leu.2014.19024919806Search in Google Scholar
Eggleton P., Bremer E., Dudek E., Michalak M.: Calreticulin, a therapeutic target? Expert Opin. Ther. Targets, 2016; 20: 1137–1147EggletonP.BremerE.DudekE.MichalakM.Calreticulin, a therapeutic target?Expert Opin. Ther. Targets2016201137114710.1517/14728222.2016.116469526959400Search in Google Scholar
Elf S., Abdelfattah N.S., Chen E., Perales-Patón J., Rosen E.A., Ko A., Peisker F., Florescu N., Giannini S., Wolach O., Morgan E.A., Tothova Z., Losman J.A., Schneider R.K., Al-Shahrour F., et al.: Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov., 2016; 6: 368–381ElfS.AbdelfattahN.S.ChenE.Perales-PatónJ.RosenE.A.KoA.PeiskerF.FlorescuN.GianniniS.WolachO.MorganE.A.TothovaZ.LosmanJ.A.SchneiderR.K.Al-ShahrourF.Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformationCancer Discov.2016636838110.1158/2159-8290.CD-15-1434485186626951227Search in Google Scholar
Falchi M., Varricchio L., Martelli F., Marra M., Picconi O., Tafuri A., Girelli G., Uversky V.N., Migliaccio A.R.: The calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Exp. Hematol., 2017; 50: 53–76FalchiM.VarricchioL.MartelliF.MarraM.PicconiO.TafuriA.GirelliG.UverskyV.N.MigliaccioA.R.The calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia veraExp. Hematol.201750537610.1016/j.exphem.2017.02.001577985228232234Search in Google Scholar
Fucikova J., Becht E., Iribarren K., Goc J., Remark R., Damotte D., Alifano M., Devi P., Biton J., Germain C., Lupo A., Fridman W.H., Dieu-Nosjean M.C., Kroemer G., Sautès-Fridman C., et al.: Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res., 2016; 76: 1746–1756FucikovaJ.BechtE.IribarrenK.GocJ.RemarkR.DamotteD.AlifanoM.DeviP.BitonJ.GermainC.LupoA.FridmanW.H.Dieu-NosjeanM.C.KroemerG.Sautès-FridmanC.Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosisCancer Res.2016761746175610.1158/0008-5472.CAN-15-114226842877Search in Google Scholar
Fucikova J., Kline J.P., Galluzzi L., Spisek R.: Calreticulin arms NK cells against leukemia. Oncoimmunology, 2020; 9: 1671763FucikovaJ.KlineJ.P.GalluzziL.SpisekR.Calreticulin arms NK cells against leukemiaOncoimmunology20209167176310.1080/2162402X.2019.1671763695945132002282Search in Google Scholar
Fucikova J., Moserova I., Urbanova L., Bezu L., Kepp O., Cremer I., Salek C., Strnad P., Kroemer G., Galluzzi L., Spisek R.: Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front. Immunol., 2015; 6: 402FucikovaJ.MoserovaI.UrbanovaL.BezuL.KeppO.CremerI.SalekC.StrnadP.KroemerG.GalluzziL.SpisekR.Prognostic and predictive value of DAMPs and DAMP-associated processes in cancerFront. Immunol.2015640210.3389/fimmu.2015.00402452828126300886Search in Google Scholar
Fucikova J., Truxova I., Hensler M., Becht E., Kasikova L., Moserova I., Vosahlikova S., Klouckova J., Church S.E., Cremer I., Kepp O., Kroemer G., Galluzzi L., Salek C., Spisek R.: Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood, 2016; 128: 3113–3124FucikovaJ.TruxovaI.HenslerM.BechtE.KasikovaL.MoserovaI.VosahlikovaS.KlouckovaJ.ChurchS.E.CremerI.KeppO.KroemerG.GalluzziL.SalekC.SpisekR.Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patientsBlood20161283113312410.1158/2326-6074.CRICIMTEATIAACR18-A072Search in Google Scholar
Galluzzi L., Buqué A., Kepp O., Zitvogel L., Kroemer G.: Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol., 2017; 17: 97–111GalluzziL.BuquéA.KeppO.ZitvogelL.KroemerG.Immunogenic cell death in cancer and infectious diseaseNat. Rev. Immunol.2017179711110.1038/nri.2016.10727748397Search in Google Scholar
Guo L., Nakamura K., Lynch J., Opas M., Olson E.N., Agellon L.B., Michalak M.: Cardiac-specific expression of calcineurin reverses embryonic lethality in calreticulin-deficient mouse. J. Biol. Chem., 2002; 277: 50776–50779GuoL.NakamuraK.LynchJ.OpasM.OlsonE.N.AgellonL.B.MichalakM.Cardiac-specific expression of calcineurin reverses embryonic lethality in calreticulin-deficient mouseJ. Biol. Chem.2002277507765077910.1074/jbc.M20990020012377773Search in Google Scholar
Han A., Li C., Zahed T., Wong M., Smith I., Hoedel K., Green D., Boiko A.D.: Calreticulin is a critical cell survival factor in malignant neoplasms. PLoS Biol., 2019; 17: e3000402HanA.LiC.ZahedT.WongM.SmithI.HoedelK.GreenD.BoikoA.D.Calreticulin is a critical cell survival factor in malignant neoplasmsPLoS Biol.201917e300040210.1371/journal.pbio.3000402676845731568485Search in Google Scholar
Han L., Schubert C., Köhler J., Schemionek M., Isfort S., Brümmendorf T.H., Koschmieder S., Chatain N.: Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J. Hematol. Oncol., 2016; 9: 45HanL.SchubertC.KöhlerJ.SchemionekM.IsfortS.BrümmendorfT.H.KoschmiederS.ChatainN.Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretionJ. Hematol. Oncol.201694510.1186/s13045-016-0275-0489437327177927Search in Google Scholar
Hellman K., Alaiya A.A., Schedvins K., Steinberg W., Hellström A.C., Auer G.: Protein expression patterns in primary carcinoma of the vagina. Br. J. Cancer, 2004; 91: 319–326HellmanK.AlaiyaA.A.SchedvinsK.SteinbergW.HellströmA.C.AuerG.Protein expression patterns in primary carcinoma of the vaginaBr. J. Cancer20049131932610.1038/sj.bjc.6601944240980715199389Search in Google Scholar
Holmström M.O., Cordua S., Skov V., Kjær L., Pallisgaard N., Ellervik C., Hasselbalch H.C., Andersen M.H.: Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. Cancer Immunol. Immunother., 2020; 69: 315–324HolmströmM.O.CorduaS.SkovV.KjærL.PallisgaardN.EllervikC.HasselbalchH.C.AndersenM.H.Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancerCancer Immunol. Immunother.20206931532410.1007/s00262-019-02473-y31915854Search in Google Scholar
Holmström M.O., Martinenaite E., Ahmad S.M., Met Ö., Friese C., Kjær L., Riley C.H., Thor Straten P., Svane I.M., Hasselbalch H.C., Andersen M.H.: The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia, 2018; 32: 429–437HolmströmM.O.MartinenaiteE.AhmadS.M.MetÖ.FrieseC.KjærL.RileyC.H.Thor StratenP.SvaneI.M.HasselbalchH.C.AndersenM.H.The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapyLeukemia20183242943710.1038/leu.2017.21428676668Search in Google Scholar
How J., Hobbs G.S., Mullally A.: Mutant calreticulin in myeloproliferative neoplasms. Blood, 2019; 134: 2242–2248HowJ.HobbsG.S.MullallyA.Mutant calreticulin in myeloproliferative neoplasmsBlood20191342242224810.1182/blood.2019000622692366831562135Search in Google Scholar
Hsu W.M., Hsieh F.J., Jeng Y.M., Kuo M.L., Chen C.N., Lai D.M., Hsieh L.J., Wang B.T., Tsao P.N., Lee H., Lin M.T., Lai H.S., Chen W.J.: Calreticulin expression in neuroblastoma - a novel independent prognostic factor. Ann. Oncol., 2005; 16: 314–321HsuW.M.HsiehF.J.JengY.M.KuoM.L.ChenC.N.LaiD.M.HsiehL.J.WangB.T.TsaoP.N.LeeH.LinM.T.LaiH.S.ChenW.J.Calreticulin expression in neuroblastoma - a novel independent prognostic factorAnn. Oncol.20051631432110.1093/annonc/mdi06215668290Search in Google Scholar
Jo S.H., Choi J.A., Lim Y.J., Lee J., Cho S.N., Oh S.M., Go D., Kim S.H., Song C.H.: Calreticulin modulates the intracellular survival of mycobacteria by regulating ER-stress-mediated apoptosis. Onco-target, 2017; 8: 58686–58698JoS.H.ChoiJ.A.LimY.J.LeeJ.ChoS.N.OhS.M.GoD.KimS.H.SongC.H.Calreticulin modulates the intracellular survival of mycobacteria by regulating ER-stress-mediated apoptosisOnco-target20178586865869810.18632/oncotarget.17419560168428938588Search in Google Scholar
Kageyama S., Isono T., Matsuda S., Ushio Y., Satomura S., Terai A., Arai Y., Kawakita M., Okada Y., Yoshiki T.: Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. Int. J. Urol., 2009; 16: 481–486KageyamaS.IsonoT.MatsudaS.UshioY.SatomuraS.TeraiA.AraiY.KawakitaM.OkadaY.YoshikiT.Urinary calreticulin in the diagnosis of bladder urothelial carcinomaInt. J. Urol.20091648148610.1111/j.1442-2042.2009.02287.x19389084Search in Google Scholar
Kasikova L., Hensler M., Truxova I., Skapa P., Laco J., Belicova L., Praznovec I., Vosahlikova S., Halaska M.J., Brtnicky T., Rob L., Presl J., Kostun J., Cremer I., Ryska A., et al.: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. J. Immunother. Cancer, 2019; 7: 312KasikovaL.HenslerM.TruxovaI.SkapaP.LacoJ.BelicovaL.PraznovecI.VosahlikovaS.HalaskaM.J.BrtnickyT.RobL.PreslJ.KostunJ.CremerI.RyskaA.Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patientsJ. Immunother. Cancer2019731210.1186/s40425-019-0781-z686869431747968Search in Google Scholar
Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., Them N.C., Berg T., Gisslinger B., Pietra D., Chen D., Vladimer G.I., Bagienski K., Milanesi C., Casetti I.C., et al.: Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med., 2013; 369: 2379–2390KlampflT.GisslingerH.HarutyunyanA.S.NivarthiH.RumiE.MilosevicJ.D.ThemN.C.BergT.GisslingerB.PietraD.ChenD.VladimerG.I.BagienskiK.MilanesiC.CasettiI.C.Somatic mutations of calreticulin in myeloproliferative neoplasmsN. Engl. J. Med.20133692379239010.1056/NEJMoa131134724325356Search in Google Scholar
Limjindaporn T., Wongwiwat W., Noisakran S., Srisawat C., Netsawang J., Puttikhunt C., Kasinrerk W., Avirutnan P., Thiemmeca S., Sriburi R., Sittisombut N., Malasit P., Yenchitsomanus P.: Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones facilitates dengue virus production. Biochem. Biophys. Res. Commun., 2009; 379: 196–200LimjindapornT.WongwiwatW.NoisakranS.SrisawatC.NetsawangJ.PuttikhuntC.KasinrerkW.AvirutnanP.ThiemmecaS.SriburiR.SittisombutN.MalasitP.YenchitsomanusP.Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones facilitates dengue virus productionBiochem. Biophys. Res. Commun.200937919620010.1016/j.bbrc.2008.12.07019105951Search in Google Scholar
Liu P., Zhao L., Kroemer G., Kepp O.: Secreted calreticulin mutants subvert anticancer immunosurveillance. OncoImmunology, 2019; 9: 1708126LiuP.ZhaoL.KroemerG.KeppO.Secreted calreticulin mutants subvert anticancer immunosurveillanceOncoImmunology20199170812610.1080/2162402X.2019.1708126695945432002304Search in Google Scholar
Liu P., Zhao L., Loos F., Marty C., Xie W., Martins I., Lachkar S., Qu B., Waeckel-Énée E., Plo I., Vainchenker W., Perez F., Rodriguez D., López-Otin C., van Endert P., et al.: Immunosuppression by mutated calreticulin released from malignant cells. Mol. Cell, 2020; 77: 748–760.e9LiuP.ZhaoL.LoosF.MartyC.XieW.MartinsI.LachkarS.QuB.Waeckel-ÉnéeE.PloI.VainchenkerW.PerezF.RodriguezD.López-OtinC.van EndertP.Immunosuppression by mutated calreticulin released from malignant cellsMol. Cell202077748760.e910.1016/j.molcel.2019.11.00431785928Search in Google Scholar
Lu Y.C., Weng W.C., Lee H.: Functional roles of calreticulin in cancer biology. Biomed. Res. Int., 2015; 2015: 526524LuY.C.WengW.C.LeeH.Functional roles of calreticulin in cancer biologyBiomed. Res. Int.2015201552652410.1155/2015/526524439601625918716Search in Google Scholar
Lwin Z.M., Guo C., Salim A., Yip G.W., Chew F.T., Nan J., Thike A.A., Tan P.H., Bay B.H.: Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod. Pathol., 2010; 23: 1559–1566LwinZ.M.GuoC.SalimA.YipG.W.ChewF.T.NanJ.ThikeA.A.TanP.H.BayB.H.Clinicopathological significance of calreticulin in breast invasive ductal carcinomaMod. Pathol.2010231559156610.1038/modpathol.2010.17320834237Search in Google Scholar
Lynch J., Guo L., Gelebart P., Chilibeck K., Xu J., Molkentin J.D., Agellon L.B., Michalak M.: Calreticulin signals upstream of calcineurin and MEF2C in a critical Ca2+-dependent signaling cascade. J. Cell Biol., 2005; 170: 37–47LynchJ.GuoL.GelebartP.ChilibeckK.XuJ.MolkentinJ.D.AgellonL.B.MichalakM.Calreticulin signals upstream of calcineurin and MEF2C in a critical Ca2+-dependent signaling cascadeJ. Cell Biol.2005170374710.1083/jcb.200412156217139215998798Search in Google Scholar
Margolin E., Oh Y.J., Verbeek M., Naude J., Ponndorf D., Mesh-cheriakova Y.A., Peyret H., van Diepen M.T., Chapman R., Meyers A.E., Lomonossoff G.P., Matoba N., Williamson A.L., Rybicki E.P.: Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plants. Plant Biotechnol. J., 2020; 18: 2109–2117MargolinE.OhY.J.VerbeekM.NaudeJ.PonndorfD.Mesh-cheriakovaY.A.PeyretH.van DiepenM.T.ChapmanR.MeyersA.E.LomonossoffG.P.MatobaN.WilliamsonA.L.RybickiE.P.Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plantsPlant Biotechnol. J.2020182109211710.1111/pbi.13369754001432096288Search in Google Scholar
Marty C., Pecquet C., Nivarthi H., El-Khoury M., Chachoua I., Tulliez M., Villeval J.L., Raslova H., Kralovics R., Constantinescu S.N., Plo I., Vainchenker W.: Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood, 2016; 127: 1317–1324MartyC.PecquetC.NivarthiH.El-KhouryM.ChachouaI.TulliezM.VillevalJ.L.RaslovaH.KralovicsR.ConstantinescuS.N.PloI.VainchenkerW.Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosisBlood20161271317132410.1182/blood-2015-11-67957126608331Search in Google Scholar
Mesaeli N., Nakamura K., Zvaritch E., Dickie P., Dziak E., Krause K.H., Opas M., MacLennan D.H., Michalak M.: Calreticulin is essential for cardiac development. J. Cell Biol., 1999; 144: 857–868MesaeliN.NakamuraK.ZvaritchE.DickieP.DziakE.KrauseK.H.OpasM.MacLennanD.H.MichalakM.Calreticulin is essential for cardiac developmentJ. Cell Biol.199914485786810.1083/jcb.144.5.857214818610085286Search in Google Scholar
Michalak M., Groenendyk J., Szabo E., Gold L.I., Opas M.: Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem. J., 2009; 417: 651–666MichalakM.GroenendykJ.SzaboE.GoldL.I.OpasM.Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulumBiochem. J.200941765166610.1042/BJ2008184719133842Search in Google Scholar
Migliaccio A.R., Uversky V.N.: Dissecting physical structure of calreticulin, an intrinsically disordered Ca2+-buffering chaperone from endoplasmic reticulum. J. Biomol. Struct. Dyn., 2018; 36: 1617–1636MigliaccioA.R.UverskyV.N.Dissecting physical structure of calreticulin, an intrinsically disordered Ca2+-buffering chaperone from endoplasmic reticulumJ. Biomol. Struct. Dyn.2018361617163610.1080/07391102.2017.1330224624314328504081Search in Google Scholar
Nakamura K., Zuppini A., Arnaudeau S., Lynch J., Ahsan I., Krause R., Papp S., De Smedt H., Parys J.B., Muller-Esterl W., Lew D.P., Krause K.H., Demaurex N., Opas M., Michalak M.: Functional specialization of calreticulin domains. J. Cell Biol., 2001; 154: 961–972NakamuraK.ZuppiniA.ArnaudeauS.LynchJ.AhsanI.KrauseR.PappS.De SmedtH.ParysJ.B.Muller-EsterlW.LewD.P.KrauseK.H.DemaurexN.OpasM.MichalakM.Functional specialization of calreticulin domainsJ. Cell Biol.200115496197210.1083/jcb.200102073219619511524434Search in Google Scholar
Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., Avezov E., Li J., Kollmann K., Kent D.G., Aziz A., Godfrey A.L., Hinton J., Martincorena I., Van Loo P., et al.: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med., 2013; 369: 2391–2405NangaliaJ.MassieC.E.BaxterE.J.NiceF.L.GundemG.WedgeD.C.AvezovE.LiJ.KollmannK.KentD.G.AzizA.GodfreyA.L.HintonJ.MartincorenaI.Van LooP.Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2N. Engl. J. Med.20133692391240510.1056/NEJMoa1312542396628024325359Search in Google Scholar
Nguyen T.O., Capra J.D., Sontheimer R.D.: Calreticulin is transcriptionally upregulated by heat shock, calcium and heavy metals. Mol. Immunol., 1996; 33: 379–386NguyenT.O.CapraJ.D.SontheimerR.D.Calreticulin is transcriptionally upregulated by heat shock, calcium and heavy metalsMol. Immunol.19963337938610.1016/0161-5890(95)00149-2Search in Google Scholar
Ostwald T.J., MacLennan D.H.: Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum. J. Biol. Chem., 1974; 249: 974–979OstwaldT.J.MacLennanD.H.Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulumJ. Biol. Chem.197424997497910.1016/S0021-9258(19)43026-3Search in Google Scholar
Païdassi H., Tacnet-Delorme P., Verneret M., Gaboriaud C., Houen G., Duus K., Ling W.L., Arlaud G.J., Frachet P.: Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition. J. Mol. Biol., 2011; 408: 277–290PaïdassiH.Tacnet-DelormeP.VerneretM.GaboriaudC.HouenG.DuusK.LingW.L.ArlaudG.J.FrachetP.Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognitionJ. Mol. Biol.201140827729010.1016/j.jmb.2011.02.02921352829Search in Google Scholar
Papp S., Fadel M.P., Kim H., McCulloch C.A., Opas M.: Calreticulin affects fibronectin-based cell-substratum adhesion via the regulation of c-Src activity. J. Biol. Chem., 2007; 282: 16585–16598PappS.FadelM.P.KimH.McCullochC.A.OpasM.Calreticulin affects fibronectin-based cell-substratum adhesion via the regulation of c-Src activityJ. Biol. Chem.2007282165851659810.1074/jbc.M70101120017389592Search in Google Scholar
Park S., Huh H.J., Mun Y.C., Seong C.M., Chung W.S., Chung H.S., Huh J.: Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemia. Cancer Genet., 2015; 208: 630–635ParkS.HuhH.J.MunY.C.SeongC.M.ChungW.S.ChungH.S.HuhJ.Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemiaCancer Genet.201520863063510.1016/j.cancergen.2015.11.00126640226Search in Google Scholar
Peng R.Q., Chen Y.B., Ding Y., Zhang R., Zhang X., Yu X.J., Zhou Z.W., Zeng Y.X., Zhang X.S.: Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J. Gastroenterol., 2010; 16: 2428–2434PengR.Q.ChenY.B.DingY.ZhangR.ZhangX.YuX.J.ZhouZ.W.ZengY.X.ZhangX.S.Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancerWorld J. Gastroenterol.2010162428243410.3748/wjg.v16.i19.2428287415020480531Search in Google Scholar
Pietra D., Rumi E., Ferretti V.V., Di Buduo C.A., Milanesi C., Cavalloni C., Sant’Antonio E., Abbonante V., Moccia F., Casetti I.C., Bellini M., Renna M.C., Roncoroni E., Fugazza E., Astori C., et al.: Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia, 2016; 30: 431–438PietraD.RumiE.FerrettiV.V.Di BuduoC.A.MilanesiC.CavalloniC.Sant’AntonioE.AbbonanteV.MocciaF.CasettiI.C.BelliniM.RennaM.C.RoncoroniE.FugazzaE.AstoriC.Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasmsLeukemia20163043143810.1038/leu.2015.277474045226449662Search in Google Scholar
Qiu Y., Lynch J., Guo L., Yatsula B., Perkins A.S., Michalak M.: Regulation of the calreticulin gene by GATA6 and Evi-1 transcription factors. Biochemistry, 2008; 47: 3697–3704QiuY.LynchJ.GuoL.YatsulaB.PerkinsA.S.MichalakM.Regulation of the calreticulin gene by GATA6 and Evi-1 transcription factorsBiochemistry2008473697370410.1021/bi702524v18303859Search in Google Scholar
Saito Y., Ihara Y., Leach M.R., Cohen-Doyle M.F., Williams D.B.: Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteins. EMBO J., 1999; 18: 6718–6729SaitoY.IharaY.LeachM.R.Cohen-DoyleM.F.WilliamsD.B.Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteinsEMBO J.1999186718672910.1093/emboj/18.23.6718117173410581245Search in Google Scholar
Schcolnik-Cabrera A., Oldak B., Juárez M., Cruz-Rivera M., Flisser A., Mendlovic F.: Calreticulin in phagocytosis and cancer: Opposite roles in immune response outcomes. Apoptosis, 2019; 24: 245–255Schcolnik-CabreraA.OldakB.JuárezM.Cruz-RiveraM.FlisserA.MendlovicF.Calreticulin in phagocytosis and cancer: Opposite roles in immune response outcomesApoptosis20192424525510.1007/s10495-019-01532-030929105Search in Google Scholar
Sheng W., Chen C., Dong M., Zhou J., Liu Q., Dong Q., Li F.: Over-expression of calreticulin contributes to the development and progression of pancreatic cancer. J. Cell. Physiol., 2014; 229: 887–897ShengW.ChenC.DongM.ZhouJ.LiuQ.DongQ.LiF.Over-expression of calreticulin contributes to the development and progression of pancreatic cancerJ. Cell. Physiol.201422988789710.1002/jcp.2451924264800Search in Google Scholar
Shide K., Kameda T., Yamaji T., Sekine M., Inada N., Kamiunten A., Akizuki K., Nakamura K., Hidaka T., Kubuki Y., Shimoda H., Kitanaka A., Honda A., Sawaguchi A., Abe H., et al.: Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia, 2017; 31: 1136–1144ShideK.KamedaT.YamajiT.SekineM.InadaN.KamiuntenA.AkizukiK.NakamuraK.HidakaT.KubukiY.ShimodaH.KitanakaA.HondaA.SawaguchiA.AbeH.Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinibLeukemia2017311136114410.1038/leu.2016.308542079327807369Search in Google Scholar
Shivarov V., Ivanova M., Tiu R.V.: Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca2+: Some mechanistic and therapeutic implications. Blood Cancer J., 2014; 4: e185ShivarovV.IvanovaM.TiuR.V.Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca2+: Some mechanistic and therapeutic implicationsBlood Cancer J.20144e18510.1038/bcj.2014.7394466424562385Search in Google Scholar
Stanley R.F., Steidl U.: Molecular mechanism of mutant CALR-mediated transformation. Cancer Discov., 2016; 6: 344–346StanleyR.F.SteidlU.Molecular mechanism of mutant CALR-mediated transformationCancer Discov.2016634434610.1158/2159-8290.CD-16-0238483298127045016Search in Google Scholar
Szuber N., Lamontagne B., Busque L.: Novel germline mutations in the calreticulin gene: Implications for the diagnosis of myeloproliferative neoplasms. J. Clin. Pathol., 2016; 69: 1033–1036SzuberN.LamontagneB.BusqueL.Novel germline mutations in the calreticulin gene: Implications for the diagnosis of myeloproliferative neoplasmsJ. Clin. Pathol.2016691033103610.1136/jclinpath-2016-20394027466382Search in Google Scholar
Tefferi A., Wassie E.A., Guglielmelli P., Gangat N., Belachew A.A., Lasho T.L., Finke C., Ketterling R.P., Hanson C.A., Pardanani A., Wolanskyj A.P., Maffioli M., Casalone R., Pacilli A., Vannucchi A.M., et al.: Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am. J. Hematol., 2014; 89: E121–E124TefferiA.WassieE.A.GuglielmelliP.GangatN.BelachewA.A.LashoT.L.FinkeC.KetterlingR.P.HansonC.A.PardananiA.WolanskyjA.P.MaffioliM.CasaloneR.PacilliA.VannucchiA.M.Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patientsAm. J. Hematol.201489E121E12410.1002/ajh.2374324753125Search in Google Scholar
Truxova I., Kasikova L., Salek C., Hensler M., Lysak D., Holicek P., Bilkova P., Holubova M., Chen X., Mikyskova R., Reinis M., Kovar M., Tomalova B., Kline J.P., Galluzzi L., et al.: Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica, 2020; 105: 1868–1878TruxovaI.KasikovaL.SalekC.HenslerM.LysakD.HolicekP.BilkovaP.HolubovaM.ChenX.MikyskovaR.ReinisM.KovarM.TomalovaB.KlineJ.P.GalluzziL.Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patientsHaematologica20201051868187810.3324/haematol.2019.223933732763831582537Search in Google Scholar
Vainchenker W., Kralovics R.: Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood, 2017; 129: 667–679VainchenkerW.KralovicsR.Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasmsBlood201712966767910.1182/blood-2016-10-69594028028029Search in Google Scholar
Vaksman O., Davidson B., Tropé C., Reich R.: Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum. Pathol., 2013; 44: 2677–2683VaksmanO.DavidsonB.TropéC.ReichR.Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastasesHum. Pathol.2013442677268310.1016/j.humpath.2013.07.00924060004Search in Google Scholar
Varricchio L., Falchi M., Dall’Ora M., De Benedittis C., Ruggeri A., Uversky V.N., Migliaccio A.R.: Calreticulin: Challenges posed by the intrinsically disordered nature of calreticulin to the study of its function. Front. Cell Dev. Biol., 2017; 5: 96VarricchioL.FalchiM.Dall’OraM.De BenedittisC.RuggeriA.UverskyV.N.MigliaccioA.R.Calreticulin: Challenges posed by the intrinsically disordered nature of calreticulin to the study of its functionFront. Cell Dev. Biol.201759610.3389/fcell.2017.00096570371529218307Search in Google Scholar
Wijeyesakere S.J., Bedi S.K., Huynh D., Raghavan M.: The C-terminal acidic region of calreticulin mediates phosphatidylserine binding and apoptotic cell phagocytosis. J. Immunol., 2016; 196: 3896–3909WijeyesakereS.J.BediS.K.HuynhD.RaghavanM.The C-terminal acidic region of calreticulin mediates phosphatidylserine binding and apoptotic cell phagocytosisJ. Immunol.20161963896390910.4049/jimmunol.1502122522254927036911Search in Google Scholar
Wijeyesakere S.J., Gagnon J.K., Arora K., Brooks C.L.3rd, Raghavan M.: Regulation of calreticulin-major histocompatibility complex (MHC) class I interactions by ATP. Proc. Natl. Acad. Sci. USA, 2015; 112: E5608–E5617WijeyesakereS.J.GagnonJ.K.AroraK.BrooksC.L.3rdRaghavanM.Regulation of calreticulin-major histocompatibility complex (MHC) class I interactions by ATPProc. Natl. Acad. Sci. USA2015112E5608E561710.1073/pnas.1510132112461159826420867Search in Google Scholar
Yue X., Wang H., Zhao F., Liu S., Wu J., Ren W., Zhu Y.: Hepatitis B virus-induced calreticulin protein is involved in IFN resistance. J. Immunol., 2012; 189: 279–286YueX.WangH.ZhaoF.LiuS.WuJ.RenW.ZhuY.Hepatitis B virus-induced calreticulin protein is involved in IFN resistanceJ. Immunol.201218927928610.4049/jimmunol.110340522661095Search in Google Scholar
Zamanian M., Veerakumarasivam A., Abdullah S., Rosli R.: Calreticulin and cancer. Pathol. Oncol. Res., 2013; 19: 149–154ZamanianM.VeerakumarasivamA.AbdullahS.RosliR.Calreticulin and cancerPathol. Oncol. Res.20131914915410.1007/s12253-012-9600-223392843Search in Google Scholar